Conference Call with Granules India Management and Analysts on Q2FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Granules India announced Q2FY25 results Revenue from Operations of Q2FY25 stood at Rs 9,666 million, a decline of 19% YoY. The Company has voluntarily paused production in the Gagillapur plant in Sep-24 to reassess the potential risk on account of the US FDA observations, if any. Subsequently in October, the production was resumed in a staggered manner. Revenue share from the North America increased to 79% in Q2FY25 as compared to 67% in Q2FY24. Finished dosages (FD), Active Pharmaceuticals Ingredients (API) and Pharmaceutical Formulation Intermediates (PFI) contributed 77%, 15%, and 8% of revenue from operations respectively for Q2FY25. ROCE is at 16.9% as compared to 12.9% YoY. Net debt stood at Rs 7,973 mn and Net debt to EBITDA at 0.86x. Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India, said: “Q2 sales were impacted by a voluntary pause in manufacturing and distribution from our Gagillapur facility. We delivered strong margins, supported by profitable formulations sales and a favourable product mix. Our operations also generated a healthy cash from operations of Rs. 2,007 million.” Result PDF